First In Human Randomised Trial of Rincell-1 in Adults With a Cochlear Implant

Rinri Therapeutics is conducting a clinical trial of a new cell therapy called Rincell-1. Rincell-1 is being developed to treat adults with neural hearing loss, either age related hearing loss or auditory neuropathy, who also meet criteria for a cochlear implant. The goals of this study are: * To learn about the safety profile of Rincell-1, the procedure used to inject it and the medications given to promote the growth of the cells * To evaluate how well Rincell-1 works by measuring changes in the function of auditory neurons. * To understand if Rincell-1 can be easily and successfully given at the same time as cochlear implant surgery Participants will be randomly assigned to one of two groups: one group that receives a standard care cochlear implant, and the other that will receive an injection of Rincell-1 at the same time as their standard care cochlear implant. Researchers will compare the safety of Rincell-1 in combination with a cochlear implant to a cochlear implant on its own. Participants will take part in the trial for 52 weeks after CI surgery. During that time, they will have regular follow-ups and will take daily measurements at home of their hearing health.

NCT Number	NCT07032038
Lead Sponsor	Rinri Therapeutics Collaborators: King's College London
Conditions	Sensorineural Hearing Loss, Presbyacusis, Auditory Neuropathy
Enrollment	20 participants
Start Date	2026-11
Primary Completion	2028-07 (estimated)
Study Completion	2028-10 (estimated)
Updated on ClinicalTrials.gov	2026-08-11